Summers Robert W
Division of Gastroenterology and Hepatology, Department of Internal Medicine, 4545 JCP, University of Iowa, Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA 52242, USA.
Surg Clin North Am. 2007 Jun;87(3):727-41. doi: 10.1016/j.suc.2007.03.004.
The treatment of inflammatory bowel disease (IBD) is undergoing rapid and profound change. Entirely new approaches are being developed that reflect a greater understanding of how to control the inflammatory process. These began with inflixumab therapy for Crohn's disease. Additional tumor necrosis antibodies will soon be employed, and other biological agents are being investigated. Probiotics, helminth ova therapy, alternative and complementary treatments, leukocytophoresis, and bone-marrow and stem-cell transplantation are additional exciting regimens that are being explored. Although some of these approaches provide marked improvement in these parameters, others are unproven or fraught with adverse effects and complications. Still, control of ulcerative colitis and Crohn's is improving with more changes likely to come.
炎症性肠病(IBD)的治疗正在经历迅速而深刻的变革。全新的治疗方法正在不断涌现,这反映出人们对如何控制炎症过程有了更深入的理解。这些变革始于用于治疗克罗恩病的英夫利昔单抗疗法。更多肿瘤坏死抗体即将投入使用,其他生物制剂也在研究之中。益生菌、蠕虫卵疗法、替代和补充疗法、白细胞去除术以及骨髓和干细胞移植等,都是正在探索的令人振奋的治疗方案。尽管其中一些方法在这些指标上有显著改善,但其他一些方法尚未得到证实,或者充满了不良反应和并发症。即便如此,溃疡性结肠炎和克罗恩病的控制情况正在改善,而且可能还会有更多变化。